Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

PALI

Palisade Bio Inc

2.08

Jul 07 • 04:00PM ET +0.04 (1.96%)

Healthcare Biotechnology USA Small NASD

Peers: EDIT AVXL ACIU ARTV PRLD TARA RIGL NGEN VYGR RZLT

| Held by: IWM VXF IWN IWC SURI ITOT IWO AVSC GSSC RSSL

Scroll to Statements

Index	RUT
Market Cap	361.04M
Enterprise Value	228.41M
Income	-24.15M
Sales	0.00M
Book/sh	0.76
Cash/sh	0.76
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	14
IPO	Dec 20, 2006

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	2.73
P/C	2.72
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	23.71
Current Ratio	23.71
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	No / Yes

EPS (ttm)	-1.07
EPS next Y	-0.28
EPS next Q	-0.05
EPS this Y	21.25%
EPS next Y	-20.11%
EPS next 5Y	-5.47%
EPS past 3/5Y	89.33% 88.75%
Sales past 3/5Y	- -
EPS Y/Y TTM	88.03%
Sales Y/Y TTM	-
EPS Q/Q	90.15%
Sales Q/Q	-
Earnings	May 12 AMC
EPS/Sales Surpr.	-16.55% -

Insider Own	3.59%
Insider Trans	0.55%
Inst Own	89.42%
Inst Trans	3.17%
ROA	-34.13%
ROE	-36.40%
ROIC	-18.96%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	10.64%
SMA50	8.32%
SMA200	12.20%
Trades

Shs Outstand	167.42M
Shs Float	167.35M
Short Float	18.83%
Short Ratio	8.23
Short Interest	31.52M
52W High	2.86 -27.15%
52W Low	0.53 292.45%
Volatility	9.64% 8.79%
ATR (14)	0.17
RSI (14)	55.85
Beta	1.53
Rel Volume	1.41
Avg Volume	3.83M
Volume	5,395,332

Perf Week	-6.73%
Perf Month	7.77%
Perf Quarter	7.77%
Perf Half Y	-16.80%
Perf YTD	-11.49%
Perf Year	183.38%
Perf 3Y	-92.08%
Perf 5Y	-99.92%
Perf 10Y	-100.00%
Recom	1.00
Target Price	10.67
Prev Close	2.04
Price	2.08
Change	1.96%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-09-26	Initiated	Wolfe Research	Outperform	$7
Mar-26-26	Initiated	H.C. Wainwright	Buy	$7
Feb-25-26	Initiated	Stifel	Buy	$5
Jan-09-26	Initiated	B. Riley Securities	Buy	$7
Dec-29-25	Initiated	Piper Sandler	Overweight	$25

Jun-29-26 01:49PM	PALI Stock Heads For Best Day In Seven Months Whats Driving Todays Rally? (Stocktwits) +17.99%
08:30AM	Palisade Bio Receives FDA Clearance of IND for PALI-2108 and Plans to Initiate Global Phase 2 ASCENTRA-UC Study in Ulcerative Colitis (GlobeNewswire)
Jun-11-26 08:45AM	Palisade Bio Welcomes Biopharmaceutical Industry Veterans Robert Baltera and Jordan Zwick to its Board of Directors (GlobeNewswire) +5.95%
Jun-09-26 08:45AM	Palisade Bio to Present on the Potential of PALI-2108 for Fibrostenotic Crohn's Disease at New York Academy of Sciences Symposium (GlobeNewswire)
May-27-26 09:00AM	Palisade Bio to Participate in the Jefferies Global Healthcare Conference (GlobeNewswire)
04:15PM	Loading…
May-12-26 04:15PM	Palisade Bio Reports First Quarter 2026 Financial Results and Highlights Continued Clinical Progress of PALI-2108 (GlobeNewswire)
May-05-26 08:30AM	Palisade Bio Reports Additional Phase 1a/b Data Demonstrating Colon-Targeted Exposure and Sustained IC90 Coverage Supporting Once-Daily Dosing in Ulcerative Colitis (GlobeNewswire) -7.51%
Apr-16-26 08:50AM	Palisade Bio Announces Abstract Selected for Poster Presentation at Digestive Disease Week (DDW) 2026 (GlobeNewswire)
Apr-08-26 09:00AM	Palisade Bio to Present at the Needham & Co. 25th Annual Healthcare Conference (GlobeNewswire)
Mar-30-26 04:01PM	Palisade Bio Reports Positive Topline Data from Phase 1b Clinical Study of PALI-2108 in Fibrostenotic Crohn's Disease (GlobeNewswire) -11.00%
Mar-02-26 09:00AM	Palisade Bio Announces Participation in Two Upcoming Investor Conferences (GlobeNewswire)
Mar-01-26 06:30AM	Palisade Bio Details PALI-2108 UC, Crohns Plans and Cash Runway Into 2029 at Oppenheimer Conference (MarketBeat)
Feb-23-26 08:40AM	Palisade Bio Reports Rapid Clinical, Histologic and New Mechanistic Colon Tissue RNA Sequencing Data Supporting Targeted Activity of PALI-2108 at ECCO 2026 (GlobeNewswire)
Feb-17-26 08:45AM	Palisade Bio Appoints Global IBD Precision Medicine Leader Bram Verstockt, MD, PhD to Clinical Advisory Board (GlobeNewswire)
Feb-09-26 09:00AM	Palisade Bio to Participate in the Piper Sandler Virtual Novel Targets in Immunology Symposium (GlobeNewswire)
08:45AM	Loading…
Feb-05-26 08:45AM	Palisade Bio to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference (GlobeNewswire) -5.06%
Jan-29-26 08:45AM	Palisade Bio Appoints Leading Global IBD Experts, Laurent Peyrin-Biroulet, MD, PhD and David T. Rubin, MD, to Its Clinical Advisory Board (GlobeNewswire)
Jan-16-26 08:30AM	Palisade Bio Announces Two Abstracts Selected for Poster Presentations at Leading Global Inflammatory Bowel Disease Conferences (GlobeNewswire) -5.14%
Jan-07-26 08:15AM	Palisade Bio Announces Strategic Equity Investment from the Crohn's & Colitis Foundation's IBD Ventures Program to Advance PALI-2108 (GlobeNewswire) +5.21%
Dec-30-25 08:35AM	Palisade Bio Announces Granting of Japanese Patent Covering Composition of Matter for Lead Product Candidate, PALI-2108 (GlobeNewswire)
Dec-29-25 07:52AM	Here Are Mondays Top Wall Street Analyst Research Calls: Doximity, KB Home, NVIDIA, Okta, On Holdings, Take-Two Interactive, Vail Resorts, and More (24/7 Wall St.) +15.35%
Dec-25-25 10:37AM	Palisade Bio (PALI) Soars 5% Ahead of Clinical Trial Results (Insider Monkey)
Dec-19-25 12:00PM	Palisade Bio (PALI) Upgraded to Buy: Here's What You Should Know (Zacks) +9.58%
Dec-02-25 08:45AM	Palisade Bio Strengthens Clinical Leadership Team with Appointment of James Izanec, MD, AGAF as Vice President, Clinical Development (GlobeNewswire)
Nov-25-25 08:45AM	Palisade Bio to Present at the Piper Sandler 37th Annual Healthcare Conference (GlobeNewswire) -5.70%
Nov-10-25 09:55AM	Here's Why Palisade Bio (PALI) Could be Great Choice for a Bottom Fisher (Zacks) +5.36%
Nov-06-25 12:00PM	All You Need to Know About Palisade Bio (PALI) Rating Upgrade to Buy (Zacks)
Oct-28-25 08:45AM	Palisade Bio Appoints Sharon Skare as Vice President, Global Head of Clinical Operations (GlobeNewswire) +11.45%
Oct-20-25 08:45AM	Palisade Bio Announces First Patients Dosed in Phase 1b Study of Oral First-In-Class PDE4 Inhibitor Prodrug, PALI-2108, for the Treatment of Fibrostenotic Crohn's Disease (FSCD) (GlobeNewswire) +6.90%
Oct-13-25 08:45AM	Palisade Bio Granted Canadian Patent Covering Composition of Lead Product Candidate PALI-2108 (GlobeNewswire) -7.50%
05:00PM	Loading…
Oct-09-25 05:00PM	Palisade Bio Announces Cancellation of Special Meeting of Stockholders (GlobeNewswire)
Oct-02-25 04:05PM	Palisade Bio Announces Closing of Upsized $138 Million Public Offering of Common Stock and Including Full Exercise of Over-Allotment Option (GlobeNewswire) +29.77% -5.88%
Oct-01-25 09:20AM	Palisade Bio Announces Pricing of Upsized $120 Million Underwritten Public Offering of Common Stock (GlobeNewswire) +52.38%
Sep-26-25 04:05PM	Palisade Bio Announces Adjournment of Special Meeting of Stockholders Due to Lack of Quorum (GlobeNewswire) +16.20%
Sep-18-25 04:05PM	Palisade Bio Announces Adjournment of Special Meeting of Stockholders Due to Lack of Quorum (GlobeNewswire)
Sep-17-25 09:00AM	Palisade Bio Reports Positive PALI-2108 Phase 1b Clinical Data (GlobeNewswire)
Sep-05-25 08:45AM	Palisade Bio Receives Health Canada Clearance for Phase 1b Trial of PALI-2108 in Fibrostenotic Crohn's Disease (FSCD) (GlobeNewswire)
Aug-25-25 09:00AM	Palisade Bio Releases Virtual Investor KOL Connect Segment on FSCD and Lead Candidate PALI-2108 (GlobeNewswire) -8.46%
Aug-11-25 07:04AM	Palisade reports outcomes from Phase Ib ulcerative colitis study (Clinical Trials Arena) -6.34%
Aug-07-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) -12.16%
09:15AM	Palisade Bio Reports 100% Clinical Response in Phase 1b Ulcerative Colitis Cohort with Novel PDE4 Inhibitor, PALI-2108 (GlobeNewswire)
Jul-31-25 08:45AM	Palisade Bio Receives Notice of Allowance for Composition of Matter Patent Covering Lead Product Candidate PALI-2108 in China (GlobeNewswire)
Jul-30-25 06:30AM	PALISADES ANNOUNCES CLOSING OF $8,251,800 LOAN WITH STRATEGIC INVESTOR (PR Newswire)
Jul-23-25 08:00PM	Palisade Bio Announces Exercise of Previously Issued Warrants for $3.9 Million (GlobeNewswire) +41.86% -9.02%
Jul-22-25 08:45AM	Palisade Bio Participates in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference (GlobeNewswire) -9.20%
08:40AM	JTC Team Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference Now Live (ACCESSWIRE)
Jul-09-25 08:45AM	Palisade Bio Appoints Emil Chuang, MB BS FRACP to its Board of Directors (GlobeNewswire) +5.41%
May-27-25 08:30AM	Palisade Bio Reports Positive Phase 1a Results for PALI-2108, a First-in-Class Terminal Ileum and Colon-Targeted PDE4 B/D Inhibitor for Fibrostenotic Crohn's Disease and Ulcerative Colitis (GlobeNewswire)
May-06-25 08:30AM	Palisade Bio Presents Positive Preclinical Data Highlighting Potential of PALI-2108 as a Promising Colon-Specific PDE4 Inhibitor for the Treatment of Ulcerative Colitis and Other Inflammatory Bowel Diseases (GlobeNewswire) +6.07%
May-01-25 08:30AM	Palisade Bio's AI-Driven Approach to IBD Heterogeneity and Efficacy Selected for Presentation at the 3rd Annual Precision Medicine in Inflammatory Bowel Disease Summit (GlobeNewswire)
Apr-09-25 08:30AM	Palisade Bio Completes Dosing in Phase 1a Portion of Ongoing Phase 1a/b Study of PALI-2108 (GlobeNewswire)
Mar-14-25 08:30AM	Palisade Bio Commences Dosing in First Ulcerative Colitis Patient Cohort in Ongoing Phase 1a/b Study of PALI-2108 (GlobeNewswire) +8.99%
Mar-12-25 08:30AM	Palisade Bio Announces Two Abstracts Selected to be Showcased as Poster of Distinction and Poster Presentation at Leading GI Forum, Digestive Disease Week (DDW) 2025 (GlobeNewswire) +11.70%
Mar-04-25 08:30AM	Palisade Bio Participates in Virtual Investor What This Means Segment (GlobeNewswire)
Feb-20-25 08:45AM	Palisade Bio, Inc. Announces Receipt of Cash Proceeds from Canada's SR&ED Tax Incentive Program for Reimbursement of Development Costs of PALI-2108 for Treatment of Ulcerative Colitis (UC) (GlobeNewswire)
Feb-19-25 09:00AM	Palisade Bio, Inc. Participates in the Virtual Investor Top 5 for '25 On-Demand Conference (GlobeNewswire)
Feb-10-25 08:45AM	Palisade Bio Presents Positive Preclinical Data of PALI-2108 for the Treatment of Ulcerative Colitis (GlobeNewswire) -7.20%
Jan-29-25 08:45AM	Palisade Bio Selected for Poster Presentation at the 2025 Crohn's & Colitis Congress (GlobeNewswire)
Jan-22-25 08:00AM	Palisade Bio to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar (GlobeNewswire) -5.30%
Jan-16-25 08:00AM	Palisade Bio Completes All Five SAD Cohorts and Advances to MAD Cohorts of Phase 1a/b Study of PALI-2108 for Treatment of Ulcerative Colitis (GlobeNewswire) -5.68%
Jan-03-25 05:20PM	Palisade Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +15.79%
Dec-17-24 08:30AM	Palisade Bio Appoints Brian Feagan, MD, FRCPC, to its Clinical Advisory Board (GlobeNewswire)
Dec-13-24 04:05PM	Palisade Bio Announces Closing of $5 Million Underwritten Public Offering Priced At-Market Under Nasdaq Rules (GlobeNewswire) -25.00%
Dec-12-24 12:05PM	Palisade Bio Announces Pricing of $5 Million Underwritten Public Offering Priced At-Market Under Nasdaq Rules (GlobeNewswire) +68.57%
Dec-03-24 08:15AM	Palisade Bio Announces Preliminary Data from Phase 1 Clinical Study of PALI-2108 for the Treatment of Moderate-to-Severe Ulcerative Colitis Appears to be Safe and Well Tolerated in Treated Subjects (GlobeNewswire) -5.00%
Nov-21-24 08:15AM	Palisade Bio to Present Preclinical Results for PALI-2108 Demonstrating Engagement of Key Fibrotic Pathways of Crohn's Disease and Ulcerative Colitis (UC) (GlobeNewswire)
Nov-14-24 09:00AM	Palisade Bio CMO Mitch Jones, MD, PhD, to Present at 8th Annual Antifibrotic Drug Development (AFDD) Summit (GlobeNewswire) +19.09%
Nov-12-24 08:45AM	Palisade Bio Reports Third Quarter 2024 Financial Results and Outlines Key Accomplishments and Next Steps to Advance Lead Program PALI-2108 (GlobeNewswire)
Nov-07-24 08:30AM	Palisade Bio Announces First Subject Dosed in Phase 1 Clinical Study of PALI-2108 for the Treatment of Moderate-to-Severe Ulcerative Colitis (UC) (GlobeNewswire)
Oct-31-24 08:30AM	Palisade Bio Announces Positive Data from Two Ex Vivo Translational Studies of PALI-2108 for the Treatment of Ulcerative Colitis (GlobeNewswire) -12.26%
Oct-15-24 08:00AM	Palisade Bio Announces Abstract Accepted for Presentation at the American College of Gastroenterology's (ACG) 2024 Annual Scientific Meeting (GlobeNewswire)
Oct-10-24 08:30AM	Palisade Bio Cleared by Health Canada to Commence Phase 1 Clinical Study for Lead Program, PALI-2108 for the Treatment of Ulcerative Colitis (UC) (GlobeNewswire)
Oct-08-24 08:00AM	Palisade Bio to Participate in the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC (GlobeNewswire) -7.10%
Sep-25-24 08:00AM	Palisade Bio Provides Update on Progress Toward Launch of Phase 1 Human Clinical Study for Lead Program, PALI-2108 for the Treatment of Ulcerative Colitis (GlobeNewswire) -9.66%
Sep-16-24 08:00AM	Palisade Bio Launches New Corporate Branding and Reiterates Commitment to Advancing Next-Generation Precision Therapies (GlobeNewswire)
Sep-05-24 08:00AM	Palisade Bio Reports Data Demonstrating PDE4B Expression in Patient Cohorts Could be Utilized as a Potential Marker for Patient Stratification (GlobeNewswire)
Aug-19-24 08:00AM	Palisade Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -8.38%
Aug-13-24 08:05AM	Palisade Bio Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Aug-08-24 08:00AM	Palisade Bio Selects Dose for Upcoming Phase 1 Clinical Study of PALI-2108 for Ulcerative Colitis (GlobeNewswire)
Jul-31-24 09:15AM	Palisade Bio Participates in Virtual Investor What this Means Segment (GlobeNewswire) +11.68%
Jul-29-24 08:30AM	Palisade Bio Successfully Completes Microbiome Study Confirming Bacterial Enzymes for Local Bioactivation of Lead Product Candidate, PALI-2108 (GlobeNewswire) -12.08%
Jul-19-24 08:30AM	Palisade Bio Announces European Patent Office Issued a Decision to Grant Notice for Patent for Lead Product Candidate, PALI-2108 (GlobeNewswire)
Jul-11-24 08:00AM	Palisade Bio Announces Successful Completion of First GMP Manufacturing of PALI-2108 Drug Substance and Engineering Batches of Drug Product (GlobeNewswire)
Jun-24-24 09:00AM	Palisade Bio to Participate in the Virtual Investor Closing Bell Series (GlobeNewswire)
Jun-21-24 08:15AM	Palisade Bio Provides Update on Advancement of its Strategic Collaboration with Strand Life Sciences (GlobeNewswire)
Jun-17-24 08:00AM	Final Participating Company Line-Up Announced for the Virtual Investor Pitch Conference Hosted by JTC Team Being Held June 17 - 18, 2024 (ACCESSWIRE)
Jun-14-24 09:55AM	Bears are Losing Control Over Palisade Bio (PALI), Here's Why It's a 'Buy' Now (Zacks)
Jun-11-24 08:30AM	Palisade Bio Announces Notice of Allowance for Canadian Patent Covering Lead Product Candidate, PALI-2108 (GlobeNewswire)
Jun-10-24 09:15AM	Palisade Bio to Present at the Virtual Investor Pitch Conference (GlobeNewswire)
08:00AM	JTC Team Announces Participating Company Line-Up for the Virtual Investor Pitch Conference on June 17-18, 2024 (ACCESSWIRE)
May-21-24 08:30AM	Palisade Bio's Lead Product Candidate, PALI-2108 Demonstrates Local Bioactivation and Dose Dependent Efficacy Response in Preclinical Mouse Models (GlobeNewswire) -7.52%
May-14-24 08:05AM	Palisade Bio Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
May-13-24 10:53PM	PALI Stock Earnings: Palisade Bio Beats EPS for Q1 2024 (InvestorPlace) -7.30%
May-07-24 08:30AM	Palisade Bio Appoints Margery Fischbein to its Board of Directors (GlobeNewswire) -6.62%
07:30AM	Palisade Bio Announces Closing of $4 Million Private Placement Priced At-The- Market Under Nasdaq Rules (GlobeNewswire)
May-02-24 08:30AM	Palisade Bio Announces $4 Million Private Placement Priced At-The- Market Under Nasdaq Rules (GlobeNewswire)
May-01-24 08:30AM	Palisade Bio's Lead Product Candidate, PALI-2108 Demonstrates Potent Anti-Inflammatory Effects in Ex-Vivo Study of Whole Blood Samples Challenged with Pro-Inflammatory Lipopolysaccharide (LPS) (GlobeNewswire) +17.41%
Apr-23-24 08:30AM	Palisade Bio Enters into Strategic Collaboration with Strand Life Sciences to Advance Precision Medicine Approach (GlobeNewswire) +20.08%
Apr-16-24 11:22AM	Why Is Palisade Bio (PALI) Stock Up 57% Today? (InvestorPlace) +42.55%
08:30AM	Palisade Bio Successfully Demonstrates Bioactivation of PALI-2108 In Ex-Vivo Study of Normal Healthy and Ulcerative Colitis Patients' Stool (GlobeNewswire)

Palisade Bio, Inc. is a biopharmaceutical company, which engages in the development of oral therapies for inflammatory bowel diseases. Its programs include PALI-2108 and LB1148. The company was founded on September 6, 2011 and is headquartered in Denver, CO.

CEOMr. J. D. Finley

Ph.D.Dr. Mitchell Lawrence Jones M.D.

Head of Corporate Development & Investor RelationsMr. Ramesh C. Donthamsetty

Head of Translational Science & MedicineDr. Joerg Heyer Ph.D.

VP & Head of Clinical DevelopmentDr. James Izanec M.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Jones Mitchell Lawrence	Officer	Jul 07 '26	Proposed Sale	2.04	53,000	108,120		Jul 07 05:18 PM
Finley John David	Officer	Jul 07 '26	Proposed Sale	2.07	146,798	303,343		Jul 07 04:59 PM
Baltera Robert Jr.	Director	Jul 01 '26	Buy	1.98	20,000	39,600	356,904	Jul 06 07:48 PM
Baltera Robert Jr.	Director	Jul 02 '26	Buy	1.98	10,000	19,800	366,904	Jul 06 07:48 PM
Jones Mitchell Lawrence	Chief Medical Officer	Feb 12 '26	Sale	1.75	1,989	3,481	13,263	Feb 13 08:10 PM
Finley John David	CEO, CFO	Feb 12 '26	Sale	1.75	3,896	6,818	27,353	Feb 13 08:07 PM
Williams Donald Allen	Director	Jan 16 '26	Buy	1.67	5,000	8,356	10,728	Jan 21 04:05 PM
Williams Donald Allen	Director	Jan 09 '26	Buy	1.88	5,000	9,400	5,728	Jan 13 09:43 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PALI

Palisade Bio Inc

Upgrade your Finviz experience